參考文獻 |
1 E. L. Pual, H. H. Tung, and M. Midler, “Organic Crystallization Process,” Powder Technol., 150(2),133-143 (2005).
2 K. Sato, “Polymorphic Transformations in Crystal Growth,” J. Phys. D: Appl. Phys., 26(8), B77-B84 (1993).
3 P. Barrett, B. Smith, J. Worlitschek, V. Bracken, B. O’Sullivan, and D. O’Grady, “Areview of the Use of Process Analytical Technology for the Understanding and Optimization of Production Batch Crystallization Process,” Org. Process Res. Dev., 9(3), 348-355 (2005).
4 A. Chimmalgi, D. J. Hwang, and C. P. Grigoropoulos, “Nanoscale Rapid Melting and Crystallization of Semiconductor Thin Films,” Nanoletters, 5(10), 1924-1930 (2005).
5 K. J. Kim, and H. S. Kim, “Coating of Energetic Materials Using Crystallization,” Chem. Eng. Technol., 28(8), 946 -951 (2005).
6 T. Threlfall, “Crystallization of Polymorphs: Thermodynamic Insight into the Role of Solvent,” Org. Process Res. Dev., 4(5), 384-390 (2000).
7 J. Aizenberg, “Crystallization in Patterns: A Bio-Inspired Approach,” Bell. Labs.
Tech. J., 16(15), 1295-1302 (2004).
8 A. Y. Lee, A. Ulman, and A. S. Myerson, “Crystallization of Amino Acids on Self-Assembled Monolayers of Rigid Thiols on Gold,” Langmuir, 18(15), 5886-5898 (2002).
9 S. L. Morissette, Ö. Almarsson, M. L. Peterson, J. F. Remenar, M. J. Read, A. V. Lemmo, S. Ellis, M. J. Cima, and C. R. Gardner, “High-throughput Crystallization: Polymorphs, Salts, Co-crystals and Solvates of Pharmaceutical Solids,” Adv. Drug Delivery Rev., 56(3), 275-300 (2004).
10 M. Lang, A. L. Grzesiak, and A. J. Matzger, “The Use of Polymer Heteronuclei for Crystalline Polymorph Selection,” J. Am. Chem. Soc., 124(50), 14834-14835 (2002).
11 R. Murai, S. Nakata, M. Kashii, H.Adachi, A. Niino, K. Takano, H. Mastumura, S. Murakami, T. Inoue, Y. Mori, and T. Sasaki, “Cooling-rate Screening System for Determining Protein Crystal Growth Conditions,” J. Cryst. Growth, 292(2), 433-436 (2006).
12 T. L. Threlfall, “Analysis of Organic Polymorphs a Review,” Analyst, 120(3), 2435-2460 (1995).
13 J. W. Mullin, “Crystal Habit Modification,” chapter 7 in crystallization, 3rd Ed., Butterworth-Heinemann, Oxford, p93, and pp.248-250 (1997).
14 C. Gu, V. Y. Jr, and D. J. W. Grant, “Polymorph Screening: Influence of Solvents on the Rate of Solvent-Mediated Polymorphic Transformation,” J. Pharm. Sci., 90(11), 1878-1890 (2001).
15 R. Hilfiker, “Thermodynamics of Polymorphism” chapter 2 in Polymorphism, 1st Ed., WILEY-VCH, Weinheim, pp.21-40 (2006).
16 J. Berstein, R. J. Davey, and Jan-Olav Henck, “Concomitant Polymorphs,” Angew.
Chem. Int. Ed., 38(23), 3440-3461 (1999).
17 S. R. Chemburkar, J. Bauer, K. Deming, H. Spiwek, K. Patel, J. Morris, R. Henry, S. Spanton, W. Dziki, W. Porter, J. Quick, P. Bauer, J. Donaubauer, B. A. Narayanan, M. Soldani, D. Riley, and K. McFarland,
“Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development,” Org. Res. Des. Dev., 4(5), 413-417 (2000).
18 S. Byran, K. Morris, and S. Comella, “Reducing Time to Market with a Science-Based Produce Management Strategy,” Pharm. Technol., 29(8), 46-56 (2005).
19 J. W. Mullin, “Crystal habit modification,” chapter 6 in crystallization,3rd Ed., Butterworth-Heinemann, Oxford , pp248-250 (1997).
20 A. K. Tiwary, “Modification of Crystal Habit and its Role in Dosage From Performance,” Drug Dev. Ind. Pharm., 27(7), 699-709 (2001).
21 N. Rasenack, and B. W. Muller, “Crystal Habit and Tableting Behavior,” Int. J. Pharm., 244(1-2), 45-57 (2002).
22 P. D. Martino, M. Beccerica, E. Joiris, G. F. Palmieri, A. G.ayot, and S. Martelli, “Influence of Crystal Habit on the Compression and Densification Mechanism of Ibuprofen,” J. Cryst. Growth, 243(2), 345-355 (2002).
23 H. Cano, N. Gabas, and J. P. Canselier, “Experimental Study on the Ibuprofen Crystal Growth Morphology in Solution,” J. Cryst. Growth, 224(3-4), 35-341 (2001).
24 R. Hilfiker, “Light Microscopy” chapter 7 in Polymorphism, 1st Ed., WILEY-VCH, Weinheim, pp.189-194 (2006).
25 R. J. Roberts, and R. C. Row, “Influence of Polymorphism on the Young’s modulus and Yield Stress of Carbmazepine, Sulfathiazole and Sulfanilamide,” Int. J. Pharm., 129(16), 79-94 (1996).
26 D. C. Apperley , R. A. Fletton , R. K. Harris , R. W. Lancaster , S. Tavener , and T. L. Threlfall , “Sulfathiazole Polymorphism Studied by Magic-Angle Spinning NMR,” J. Pharm. Sci., 88(12), 1275-1280 (2000).
27 F. C. Chan, J. Anwar, R. Cernik, P. Barnes, and R. M. Wilson, “Ab Initio Structure Determination of Sulfathiazole Polymorph V Form Synchrotron X-Ray Powder Diffraction Data,” J. Appl. Cryst., 32(3), 436-441(1999).
28 G. J. Kruger, and G. Gafner, “The Crystal Structure of Sulphathiazole II,” Acta Cryst., B27(2), 326-333 (1971).
29 J. Anwar, S. E. Tarling, and P. Barnes, “Polymorphism of Sulfathiazole,” J. Pharm. Sci., 78(4), 337-342 (1989).
30 D. S. Hughes, M. B. Hursthoush, T. Threlfall, and S. Tavener, “A New Polymorph of Sulfathiazole,” Acta Cryst., C55(11),1831-1833 (1999).
31 J. E. Anderson, S. Moore, F. Tarczynski, and D. Walker, “Determination of the Onset of Crystallizayion of N1-2-(thiazolyl)sulfaniliamide (sulfathiazole) by UV-V is and Calorimetry Using an Automated Reaction Platform; Subsequent Characterization of Polymorphic Forms Using Dispersive Raman Spectroscopy,” Spect. Acta Part A., 57(4), 1793-1808 (2001).
32 A. Kordikowski, T. Shekunov, and P. York, “Polymorph Control of Sulfathiazole in Supercritical CO2,” Pharm. Res., 18(5), 682-688 (2001).
33 K. Shirotani, E. Suzuki, and K. Sekiguchi, “Solvate Formation of Sulfathiazole with Acetone, 2-Butanone, 2-Pentanone and Dioxane, and Its Application to Particle Size Reduction,” Chem. Pharm. Bull., 31(6), 2085-2093 (1983).
34 A. L. Bingham, D. S. Hughes, M. B. Hursthouse, R. W. Lancaster, S. Tavener, and T. L. Threfall, “Over One Hundred Solvates of Sulfathiazole,” Chem. Commun., 7, 603-604 (2001).
35 M. A. Mikhailenko, T. N. Drebushchak, V. A. Drebushchak, E. V. Boldyreva, and V. V. Boldyrev, “Synthesis and Characterization of Sulfathiazole-Pyridine Solvate Polymorphs,” J. Cryst. Growth, 274 (3-4), 569-572 (2005).
36 A. F. M. Barton, “Handbook and Solubility Parameters and Other Cohesion Parameters,” 2nd Ed., CRC Press, Perth, pp. 422-429 (1991).
37 W. Archer, “Hansen Solubility Parameters for Selected Cellulose Ether Derivatives and their Use in the Pharmaceutical Industry,” Drug Dev. Ind. Pharm., 18(5), 599-616 (1992).
38 J. Burke , “Solubility Parameter: Theory and Application,” AIC Book and Paper Group Annual, 3, 13-58 (1984).
39 K. M. Watson , “Prediction of critical temperatures and heats of vaporization” Ind. Engng. Chem., 23(4), 360-366 (1931).
40 B. A. Miller-Chou, and J. L. Koenig, “A Review of Polymer Dissolution,” Prog. Polym. Sci. 28 (8), 1223–1270 (2003).
41 W. I. Cross, N. Blagden, and R. J. Davey, “A Whole Output Strategy for Polymorph Screening: Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Experiments in the Case of Diflunisal,” Cryst. Growth Des. 3(2), 151 -158 (2003).
42 S. Mirza, I. Miroshnyk, J. Heinni, L. Christansen, M. Karjalainen, and J. Yliruusi, “Influence of Solvent on the Variety of Crystalline Forms of Erythromycin,” AAPS Pharm. Sci., 5(2), 1-9 (2003).
43 J. Anwar, S. E. Tarling, and P. Barnes, “Polymorphism of Sulfathiazole,” J. Pharm. Sci., 78(4), 337-342 (1989).
44 A. Burer and R. D. Dialer, “Neue Untersuchungsergebnisse Zur Polymorphie von Sulfathiazole,” Pharm. Acta Helv., 58(3), 72-78 (1983).
45 T. Threlfall, “ Crystallisation of Polymorphs: Thermodynamic Insight into the Role of Solvent,” Org. Proc. Res. Dev., 4 (5), 384 -390, (2000).
46 R. J. Davey, K. Allen, N. Blagden, W. I. Cross, H. F. Lieberman, M. J. Quayle, S. Righini, L. Seton, and G. J. T. Tiddy, “Crystal Engineering – Nucleation, the Key Step,” Cryst. Eng. Comm., 4(47), 257-264 (2002).
47 N. Blagden, R. J. Davey, H. F. Lieberman, L. Williams, R. Payne, R. Roberts, R. Rowe, and R. Docherty, “Crystal Chemistry and Solvent Effects in Polymorphic Systems Sulfathiazole,” J. Chem. Soc., Faraday Trans., 94(8), 1035-1044 (1998).
48 R. J. Davey, K. Allen, N. Blagden, W. I. Cross, H. F. Lieberman, M. J. Quayle, S. Righini, L. Seton, and G. J. T. Tiddy, “Crystal Engineering – Nucleation, the Key Step,” Cryst. Eng. Comm., 4(47), 257-264 (2002).
49 G. J. Kruger, and G. Gafner, “The Crystal Structure of Sulphathiazole II,” Acta Cryst., B27(2), 326-333 (1971).
50 J. E. Anderson, S. Moore, F. Tarczynski, and D. Walker, “Determination of the Onset of Crystallizayion of N1-2-(thiazolyl)sulfaniliamide (sulfathiazole) by UV-V is and Calorimetry Using an Automated Reaction PlatForm; Subsequent Characterization of Polymorphic Forms Using Dispersive Raman spectroscopy,” Spect. Acta Part A., 57(4), 1793-1808 (2001).
51 J. M. E. Buyan, N. Shankland, and D. B. Sheen, “Solvent Effects on the Crystal Habit of Ibuprofen,” J. Pharm. Sci., 58, 1505-1509 (1969).
52 J. M. E. Bunyan, N. Shankland, and D. B. Sheen, “Solvent Effect on the Morphology of Ibuprofen,” Particle Design via Crystallization AIChE System. Series, 87(284), 44-57 (1991).
53 F. Gharagheizi, and M. T. Angaji, “A New Improved Method for Estimating Hansen Solubility Parameters of Polymers,” J. Macromol. Sci.,45(2), 285-290 (2006).
54 F. Gharagheizi, M. Sattari, and M. T. Angaji, “Effect of Caculation Method on Values of Hansen Solubility Parameter of Polymers,” Polym. Bull., 57(3), 377-384
(2006).
55 T. C. Frank, J. R. Downey, and S. K. Gupta, “Quickly Screen Solvents for Organic
Solids,” Chem. Eng. Prog., 95(12), 41-61 (1999).
56 F. Gharagheizi, “New Procedure to Calculate the Hansen Solubility Parameters of Polymers,” J. Appl. Polym. Sci., 103(1), 31-36 (2007). |